Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
Gilead Sciences Inc.
(NASDAQ:GILD) and Merck & Co.
Inc.
(NYSE:MRK) on Tuesday reported detailed Phase 3 results showing their investigational once-weekly oral HIV regimen of islatravir and lenacapavir (ISL/LEN) maintained viral suppression through 48 weeks in adults switching from daily antiretroviral therapy.
The once-weekly single-tablet regimen met the primary endpoint in both Phase 3 studies, demonstrating non-inferior efficacy to standard daily treatment.
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what…
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral…
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
A combination of Merck’s islatravir and Gilead’s lenacapavir has
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
Lenacapavir was nearly 100 per cent effective in preventing HIV in clinical trials.
